BIND Therapeutics and Amgen Amend Collaboration Agreement for Kinase Inhibitor Nanomedicine

16-12-2013 Business Wire HealthComments (0)

AmgenBIND TherapeuticsPharmaceutical

BIND Therapeutics and Amgen Amend Collaboration Agreement for Kinase Inhibitor Nanomedicine, Extends Option Exercise Period by Six Months

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top